Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20833694 | 0.91 | BTN3A1 (0.43) | BTN3A1ALDH1A1KMT2AMRGPRX4ELANE | |
| SCHEMBL22065646 | 0.91 | POLB (0.41) | BTN3A1ALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL22065648 | 0.91 | BTN3A1 (0.39) | BTN3A1ALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL22065166 | 0.89 | BTN3A1 (0.47) | BTN3A1ALDH1A1MRGPRX4ELANECASP1 | |
| SCHEMBL22066298 | 0.89 | TACR1 (0.42) | BTN3A1ALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL22066299 | 0.89 | BTN3A1 (0.39) | BTN3A1ALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL22066006 | 0.89 | BTN3A1 (0.38) | BTN3A1ALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL22066005 | 0.89 | BTN3A1 (0.38) | BTN3A1ALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL18973570 | 0.88 | BTN3A1 (0.49) | BTN3A1ELANEPRTN3FFAR1 | |
| SCHEMBL22065165 | 0.88 | BTN3A1 (0.42) | BTN3A1ALDH1A1KMT2AMRGPRX4ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402962-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | NuCana plc (GB) | 2022-12-22 | — | — | US | disclosed |
| US-20200181186-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | NuCana plc (GB) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181186-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | PPA1, PPIP5K2, TYMP | BTN3A1 4531/4885ALDH1A1 2573/4885KDM4E 2047/4885 |
| US-20220402962-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | PNP, NTPCR, TYMP | BTN3A1 2948/4885ALDH1A1 2781/4885KDM4E 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.